Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8IYP2

UPID:
PRS58_HUMAN

ALTERNATIVE NAMES:
Trypsin-X3

ALTERNATIVE UPACC:
Q8IYP2; B3KVJ6; D3DXD2

BACKGROUND:
The enzyme Serine protease 58, alternatively referred to as Trypsin-X3, is a crucial component of the serine protease family. These enzymes are integral to numerous physiological processes, such as protein digestion and the regulation of blood coagulation. Serine protease 58's unique functions and interactions within the body underscore its importance in maintaining cellular and systemic health.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions and mechanisms of Serine protease 58 holds the promise of unveiling novel therapeutic avenues. As research progresses, the potential to develop innovative treatments targeting the pathways influenced by this enzyme increases, highlighting its significance in the field of drug discovery.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.